Trial Profile
Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in Locally Advanced Resectable Rectal Cancer: A Randomized, Non-Comparative Phase II Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Rectal cancer
- Focus Therapeutic Use
- Acronyms INOVA
- Sponsors Roche
- 04 May 2016 Status changed from active, no longer recruiting to completed.
- 19 Jan 2015 Planned End Date changed from 1 Mar 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
- 19 Jan 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov record.